SCHEMBL1616136

SCHEMBL1616136

Cc1nc(-c2cccc3nc(N[C@@H]4CCc5ccccc54)ccc23)no1

nearest known ligand 0.42

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 9/20 0.42
GBA1 P04062 2/20 0.41
PDPK1 O15530 1/20 0.37
BDKRB1 P46663 1/20 0.37
EGFR P00533 1/20 0.36
FADS1 O60427 1/20 0.36
HDAC6 Q9UBN7 1/20 0.35
KCNN3 Q9UGI6 1/20 0.35
OPRK1 P41145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616137 1.00 PFKFB3 (0.42) PFKFB3GBA1PDPK1BDKRB1EGFR
SCHEMBL1616397 0.83 PFKFB3 (0.46) PFKFB3GBA1PDPK1EGFRFADS1
SCHEMBL1616394 0.83 PFKFB3 (0.46) PFKFB3GBA1PDPK1EGFRFADS1
SCHEMBL1616241 0.82 GBA1 (0.50) PFKFB3GBA1PDPK1EGFRFADS1
SCHEMBL1616249 0.82 GBA1 (0.50) PFKFB3GBA1PDPK1EGFRFADS1
SCHEMBL3407326 0.80 PFKFB3 (0.46) PFKFB3EGFR
SCHEMBL4108833 0.80 PFKFB3 (0.46) PFKFB3EGFR
SCHEMBL1616160 0.79 PFKFB3 (0.46) PFKFB3GBA1PDPK1EGFRFADS1
SCHEMBL2245619 0.78 GBA1 (0.47) PFKFB3GBA1PDPK1EGFRFADS1
SCHEMBL3844986 0.76 PDPK1 (0.47) PFKFB3GBA1PDPK1EGFRFADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923561-B2 Quinolines HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US claimed
EP-2099763-B1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-08-11 EP claimed
EP-2099763-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-09-16 EP claimed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US claimed
WO-2008068157-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO claimed
US-7923561-B2 Quinolines HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2099763-B1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
EP-2099763-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-09-16 EP disclosed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US disclosed
WO-2008068157-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146567-A1 QUINOLINES HTR5A, HTR2B, HTR2C PFKFB3 4177/4885GBA1 662/4885PDPK1 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.